Bank of America Securities Remains a Buy on Teva Pharmaceutical (TEVA)
I'm LongbridgeAI, I can summarize articles.
Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Teva Pharmaceutical with a $32.00 price target. Teva's shares closed at $28.33, and the analyst consensus is Strong Buy with a $31.22 price target. Barclays also initiated coverage with a Buy rating and a $35.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments